CoChat

Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry

Open access
Hambly, Nathan, Farooqi, M. Malik, Dvorkin-Gheva, Anna, Donohoe, Kathryn, Garlick, Kristopher, Scallan, Ciaran, Chong, Sy Giin, MacIsaac, Sarah, Assayag, Deborah, Johannson, Kerri A., Fell, Charlene D., Marcoux, Veronica, Manganas, Helene, Morisset, Julie, Comes, Alessia, Fisher, Jolene H., Shapera, Shane, Gershon, Andrea S., To, Teresa, Wong, Alyson W., Sadatsafavi, Mohsen, Wilcox, Pierce G., Halayko, Andrew J., Khalil, Nasreen, Cox, Gerard, Richeldi, Luca, Ryerson, Christopher J., Kolb, Martin · 2022 · European Respiratory Journal
Cited by 186

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background: Progressive fibrosing interstitial lung disease (PF-ILD) is characterised by progressive physiological, symptomatic and/or radiographic worsening. The real-world prevalence and characteristics of PF-ILD remain uncertain. Methods: Patients were enrolled from the Canadian Registry for Pulmonary Fibrosis between 2015 and 2020. PF-ILD was defined as a relative forced vital capacity (FVC) decline ≥10%, death, lung transplantation or any two of: relative FVC decline ≥5% and <10%, worsening respiratory symptoms or worsening fibrosis on computed tomography of the chest, all within 24 months of diagnosis. Time-to-event analysis compared progression between key diagnostic subgroups. Characteristics associated with progression were determined by multivariable regression. Results: Of 2746 patients with fibrotic ILD (mean±sd age 65±12 years; 51% female), 1376 (50%) met PF-ILD criteria in the first 24 months of follow-up. PF-ILD occurred in 427 (59%) patients with idiopathic pulmonary fibrosis (IPF), 125 (58%) with fibrotic hypersensitivity pneumonitis (HP), 281 (51%) with unclassifiable ILD (U-ILD) and 402 (45%) with connective tissue disease-associated ILD (CTD-ILD). Compared with IPF, time to progression was similar in patients with HP (hazard ratio (HR) 0.96, 95% CI 0.79–1.17), but was delayed in patients with U-ILD (HR 0.82, 95% CI 0.71–0.96) and CTD-ILD (HR 0.65, 95% CI 0.56–0.74). Background treatment varied across diagnostic subtypes, with 66% of IPF patients receiving antifibrotic therapy, while immunomodulatory therapy was utilised in 49%, 61% and 37% of patients with CHP, CTD-ILD and U-ILD, respectively. Increasing age, male sex, gastro-oesophageal reflux disease and lower baseline pulmonary function were independently associated with progression. Conclusions: Progression is common in patients with fibrotic ILD, and is similarly prevalent in HP and IPF. Routinely collected variables help identify patients at risk for progression and may guide therapeutic strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/13993003.02571-2021

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Hambly, N., Farooqi, M. M., Dvorkin-Gheva, A., Donohoe, K., Garlick, K., Scallan, C., Chong, S. G., MacIsaac, S., Assayag, D., Johannson, K. A., Fell, C. D., Marcoux, V., Manganas, H., Morisset, J., Comes, A., Fisher, J. H., Shapera, S., Gershon, A. S., To, T., Wong, A. W., Sadatsafavi, M., Wilcox, P. G., Halayko, A. J., Khalil, N., Cox, G., Richeldi, L., Ryerson, C. J., & Kolb, M.
Venue
European Respiratory Journal
Published
2022-03-10
Volume
60
Issue
4
Pages
2102571
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W4220722717
Cited by
186
References
6
FWCI
22.27
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.